© 2019 Biosymtec Medical™

Our History

The Biosymtec™ story actually began here at a company managed by Biosymtec Medical's current CTO.   It was here he gained substantial background in monitoring and graphing the health of chronically ill people.   It is also where he gained experience in monitoring the reproductive cycles of over 400 infertility patients, adding to his experience researching infertility with the University of Illinois College of Medicine and the Medical College of Wisconsin, years earlier.

In 2004 John Beiswenger and Jody Taualofai, an RN, traveled to Hong Kong to research his discovery that respiratory infections could be detected days before fevers developed.

Beginning in 2007, he formed a research team, now on Biosymtec Medical's Advisory Board, and for 12 years they researched pre-symptomatic signs of infection, resulting in the medical device now known as the Biosymtec Monitor.

Biosymtec Medical, Inc. was incorperated in the Commonwealth of Pennsylvania early in 2019

 

Our Mission

At Biosymtec Medical, we believe that while YOU are ultimately responsible for YOUR health, it is not something you do alone. 

Your care-team includes your doctors and nursing staff, of course, but that important circle also includes family members, caregivers, and even employers, all of whom are personally vested in your health.

 

To seamlessly enable your care-team to actively participate in your care, we have developed the Biosymtec Monitor as a platform to quickly and easily connect your team.

 

By collecting and sharing your biometric data with them daily, everyone is provided advance notice of any emerging health conditions which enables early intervention and overt complications,

Early Detection

Rapid Response

Better Outcomes

 

Leadership

Tom French, CEO

Tom French possesses a 30-year professional track record creating shareholder value start-ups and turn-arounds. His holistic approach to improving business performance by seamlessly integrating market strategy with operations, sales, marketing and customer service while creating high-functioning teams establishes a platform for growth. Tom led a marketing-driven, turn-around of the largest US cable company precipitating a $48B sale to AT&T. He turned-around an innovative biotech company, secured EPA and FDA approval of technology, built a 20-item line of consumer and commercial products, achieved nation-wide distribution with#1 Pharmacy retailer and raised $4.5M to expand operations and enter new markets for this technology.

John Beiswenger, CTO

John Beiswenger has 50 years of product research, design engineering, product development, manufacturing, product management, general management, marketing and sales experience in high volume consumer and commercial hard goods.  This includes 20 years in health monitoring technology.   He has placed over 65 products into production, monitoring pilot production in the U.S., Ireland, France, Japan, Taiwan, Hong Kong and Mainland China. 

Mr. Beiswenger is named on over 30 U.S. and foreign utility patents, the most recent including color LCD touch display technology, digital alarm clock electronics, fingerprint scanning technology, surgical instrument sterilization, bioterrorism detection and predictive health monitoring technology.

Les Carlson, CMO

Les Carlson brings more than 18 years of medical product commercialization experience to Biosymtec.  His dynamic commercial leadership experience has ranged from venture capital backed startups to Fortune 50 companies. At TriPath Imaging he led the launch of a series of molecular biomarkers, leading up to the acquisition of the company by Becton Dickinson.  As a Co-Founder of Veran Medical Technologies, Les brought to market 17 surgical products and negotiated 

sole distribution agreement with GE Healthcare in the USA.  Most recently at Danaher, he spent his time reorganizing international teams yielding a 40% year over year revenue increase for the company. 

 

Advisory Board

James A. Wilson 

M.D​.

Daniel J. Colyer Beiswenger  Design Coordinator

Joseph E. Johnson, Jr. III

Biochemist

Early Detection, allows for Rapid Response, producing Better Outcomes